ReviewCancers2019
Immunotherapy Associated Pulmonary Toxicity: Biology Behind Clinical and Radiological Features.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07430501 (AcceleRating the Translation of Virtual Twins Towards a pErsonalised Management of Steatotic Liver Patients), which is not on this map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
AcceleRating the Translation of Virtual Twins Towards a pErsonalised Management of Steatotic Liver Patients
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- The current state and trends of immunotherapy research in lung cancer: a review and bibliometric analysis.Frontiers in oncology · 2024Pooled it
- Thoracoscopic biopsy should be considered for pulmonary nodules with the halo sign during immunotherapy for hepatocellular carcinoma.Clinical journal of gastroenterology · 2026Article
- [Side effects of immune checkpoint inhibitors : Focus on pulmonary events].Radiologie (Heidelberg, Germany) · 2026Review
- Optimizing inpatient care for lung cancer patients with immune checkpoint inhibitor-related pneumonitis using a clinical care pathway algorithm.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2024Article
- Optimizing Inpatient Care for Lung Cancer Patients with Immune Checkpoint Inhibitor- Related Pneumonitis Using a Clinical Care Pathway Algorithm.Research square · 2024Article
- The Clinical Analysis of Checkpoint Inhibitor Pneumonitis with Different Severities in Lung Cancer Patients: A Retrospective Study.Journal of clinical medicine · 2024Article
- Immune checkpoint targeting antibodies hold promise for combinatorial cancer therapeutics.Clinical and experimental medicine · 2023Review
- Lung Organotypic Slices Enable Rapid Quantification of Acute Radiotherapy Induced Toxicity.Cells · 2023Article
- Lung cancer immunotherapy: progress, pitfalls, and promises.Molecular cancer · 2023Review
- Article
- [Immune-related pneumonitis: A differential diagnosis of SARS-CoV-2 pneumonia].Revue des maladies respiratoires · 2022Article
- Analysis of cytokines in serum and bronchoalveolar lavage fluid in patients with immune-checkpoint inhibitor-associated pneumonitis: a cross-sectional case-control study.Journal of cancer research and clinical oncology · 2022Article
- Acetylcholine receptor binding antibody-associated myasthenia gravis, myocarditis, and rhabdomyolysis induced by tislelizumab in a patient with colon cancer: A case report and literature review.Frontiers in oncology · 2022Article
- Recent advances in immune checkpoint inhibitors for non-small lung cancer treatment.Frontiers in oncology · 2022Review
- Safety of thoracic radiotherapy after PD-(L)1 inhibitor treatment in patients with lung cancer.Cancer medicine · 2021Article
- Cellular Immunotherapy and the Lung.Vaccines · 2021Review
- Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression.Molecular diagnosis & therapy · 2021Review
- Article
- COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report.Journal for immunotherapy of cancer · 2021Article
- Biological Bases of Immune-Related Adverse Events and Potential Crosslinks With Immunogenic Effects of Radiation.Frontiers in pharmacology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The broader use of immune checkpoint blockade in clinical routine challenges clinicians in the diagnosis and management of side effects which are caused by inflammation generated by the activation of the immune response. Nearly all organs can be affected by immune-related toxicities. However, the most frequently reported are: fatigue, rash, pruritus, diarrhea, nausea/vomiting, arthralgia, decreased appetite and abdominal pain. Although these adverse events are usually mild, reversible and not frequent, an early diagnosis is crucial. Immune-related pulmonary toxicity was most frequently observed in trials of lung cancer and of melanoma patients treated with the combination of the anti-cytotoxic T lymphocyte antigen (CTLA)-4 and the anti-programmed cell death-1 (PD-1) antibodies. The most frequent immune-related adverse event in the lung is represented by pneumonitis due to the development of infiltrates in the interstitium and in the alveoli. Clinical symptoms and radiological patterns are the key elements to be considered for an early diagnosis, rendering the differential diagnosis crucial. Diagnosis of immune-related pneumonitis may imply the temporary or definitive suspension of immunotherapy, along with the start of immuno-suppressive treatments. The aim of this work is to summarize the biological bases, clinical and radiological findings of lung toxicity under immune checkpoint blockade, underlining the importance of multidisciplinary teams for an optimal early diagnosis of this side effect, with the aim to reach an improved patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.